April 1, 1989Clinical Pharmacology & Therapeutics
Pharmacokinetics and pharmacodynamics of long-term continuous-infusion doxorubicin
Why the study?
What is the pharmacodynamic relationship between steady-state doxorubicin levels and nadir WBC in patients with advanced cancer receiving long-term continuous infusion?
Population
32 patients with advanced cancer
Design
Cohort
Follow-up
2 to 50 weeks
Authors
Discussion
Loading...
Member takes
Implication
Steady-state doxorubicin levels associate with nadir WBC; hypothesis-generating for PK-guided dosing in continuous infusion, pending prospective trials.
Structured PICO
What is the pharmacodynamic relationship between steady-state doxorubicin levels and nadir WBC in patients with advanced cancer receiving long-term continuous infusion?
P
Population
32 patients with advanced cancer
I
Intervention
Doxorubicin by long-term continuous infusion at progressively increasing infusion rates (0.2 to 6.1 mg/m2/day) for 2 to 50 weeks
O
Outcome
Steady-state plasma levels of doxorubicin and doxorubicinol and their correlation with nadir WBCsurrogate
Steady-state doxorubicin levels correlate significantly with nadir WBC during long-term continuous infusion, highlighting the value of pharmacokinetic monitoring.
Cite This Study
Ackland et al. (1989) studied this question.